RxDoctor Payments Data

Anna Trubey

Nurse Practitioner · Bryan, OHNPI 1073973889

Payments from drug & device makers

$795in general payments, 2019–2025

Across 43 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$280
  • AbbVie$181
  • Exact Sciences$91
  • Novo Nordisk$57
  • Novartis$41
  • Amgen$35
  • plus $110 from 5 others

What the payments were for

  • Food & beverage$795100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca14$280
AbbVie10$181
Exact Sciences6$91
Novo Nordisk3$57
Novartis2$41
Amgen2$35
GSK2$27
Bayer1$25
Inspire Medical Systems, Inc.1$22
Pfizer1$19
BD1$16

How this compares

$795 in reported general payments places this provider in the 80th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$72,162
Medicare patients
239
Services billed
1,177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$32,251
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$31,859
OzempicSemaglutide16$22,762
TrulicityDulaglutide13$20,610
RybelsusSemaglutide17$19,796
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$15,465
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$11,527
Breo ElliptaFluticasone/Vilanterol24$11,220
FarxigaDapagliflozin Propanediol15$10,928
LinzessLinaclotide11$5,846
XareltoRivaroxaban11$5,735
Albuterol Sulfate HfaAlbuterol Sulfate103$3,037
Atorvastatin Calcium340$2,992
Famotidine108$2,557
Omeprazole170$2,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$27$43,08068 claims
Novo NordiskOzempic, Rybelsus$57$42,55833 claims
PfizerEliquis$19$32,25128 claims
AstraZenecaBreztri Aerosphere, Farxiga$280$26,39337 claims
AbbVieLinzess, Synthroid$181$6,43829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Bryan

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →